FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
J&J’s diabetes drug reduces heart risk at the cost of toes; Google’s AI eye doctor initiative
This week in Phispers, we bring you news on J&J’s Invokana, a drug that reduces heart risk